Last ¥5,860 JPY
Change Today +55.00 / 0.95%
Volume 3.2M
4502 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 1:00 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
¥5,778
Previous Close
¥5,805
Day High
¥5,895
Day Low
¥5,776
52 Week High
01/29/15 - ¥5,895
52 Week Low
10/17/14 - ¥4,338
Market Cap
4.6T
Average Volume 10 Days
3.9M
EPS TTM
¥110.56
Shares Outstanding
789.8M
EX-Date
03/27/15
P/E TM
53.0x
Dividend
¥180.00
Dividend Yield
3.07%
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and collaboration agreement with Mersana Therapeutics Inc. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Announces the Start of Phase 2/3 and Phase 3 Clinical Trials of rasagiline

Takeda Pharmaceutical Company Limited announced the start of Phase 2/3 and Phase 3 clinical trials of rasagiline (generic name, development code: TVP-1012), an investigational compound for the treatment of Parkinson's disease, in Japan. The main portion of clinical trials started this time aiming to examine efficacy and safety of rasagiline consists of a couple of multicenter, randomized, double-blind and placebo-controlled parallel-group comparative trials. One is a Phase 2/3 clinical trial conducted with the Japanese patients with Parkinson's disease under the treatment with levodopa (adjunctive therapy study), and its primary endpoint is change of mean total daily off-time. Another is a Phase 3 clinical trial conducted with the Japanese patients with early stage Parkinson’s disease (monotherapy study), and its primary endpoint is sum of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts 2 and 3 scores.

Takeda Pharmaceutical Company Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM

Takeda Pharmaceutical Company Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Christophe Weber, President, Chief Operating Officer and Representative Director.

Takeda and Otsuka Pharmaceutical Receive Approval in Japan for Acid-Related Disease Treatment Takecab

Takeda and Otsuka Pharmaceutical have received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for their Takecab (vonoprazan fumarate) treatment targeting acid-related disease. Takecab, which was discovered by Takeda, uses a novel mechanism of action called potassium-competitive acid blockers (P-CABs) that inhibits the binding of potassium ions to proton pumps during the final step of gastric acid secretion in gastric parietal cells. The approval was based on the results of several Japan-based Phase III clinical trials. Takeda has conducted trials for indications including gastric ulcer, duodenal ulcer, erosive oesophagitis, and H. pylori eradication, during which Takecab showed efficacy and a favourable profile for safety and tolerability, according to the source.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥5,860.00 JPY +55.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.41 USD -0.27
Astellas Pharma Inc ¥1,823 JPY +14.00
Baxter International Inc $70.16 USD -0.50
Becton Dickinson and Co $140.82 USD -1.40
Shire PLC 4,880 GBp +47.00
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 41.3x
Price/Sales 2.5x
Price/Book 1.7x
Price/Cash Flow 13.8x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.